Here's more science that shows us that the new jab just isn't getting a lot of support despite rising local sickness and warnings from health officials . . . Here's a peek:

Going on four years since the SARS-CoV-2 virus devastated lives and economies worldwide, health care providers and public health advocates say a growing number of people seem to have lost sight of just how dangerous the virus can be. Perhaps as a result, most people aren’t rolling up their sleeves for the latest vaccine boost.

“There is little to no interest in it,” said Carole Thomas, vice president of clinical operations for KC Care Health Center.

Nationally, just 16% of adults and 7% of children had received the latest version of the shot by the start of December, said the U.S. Centers for Disease Control and Prevention. The Kansas City Health Department administered 1,420 doses between September and early December, fewer than the number given in just one week during the height of the pandemic.

Read more via www.TonysKansasCity.com link . . .

There's 'little to no interest' in latest COVID vaccine, and health leaders worry about long-term implications

The CDC reports that only 16% of adults and 7% of children have received the updated vaccine. Hospitalizations are low in Kansas City, but providers warn the virus can still be deadly.

COVID-19 is on the rise again in Kansas City. What to know about vaccines, patient count

COVID-19 hospitalizations are on the rise in the Kansas City area, as only around 17% of adults have gotten the new vaccine nationwide.

Related & big picture . . .

Supreme Court wipes rulings on federal employee, military vaccine mandates

The Supreme Court wiped a series of rulings implicating the Biden administration's vaccine mandates for federal employees and military servicemembers, preventing the decisions from holding the weight of precedent in the future. With the mandates rescinded, the justices on Monday sided with the Biden administration in agreeing to set aside the lower rulings after deeming...

Developing . . .